Business
BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy
June 10, 2025Announcement no. 16 BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy COPENHAGEN, DENMARK and BOSTON, MA, USA, June 10, 2025, (GLOBE NEWSWIRE) - BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR) today announced the appointment of Carsten Buhl as Chief Executive Officer (CEO) of BioPorto A/S and its subsidiaries, effective 1 September 2025, as part of the Company’s succession planning strategy. BioPorto’s current CEO, Peter Mørch Erikse
About this update from Bioporto A/s
[{"type":"image","alt":"BioPorto A/S","displaySize":"","headline":null,"caption":"BioPorto A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XFhYiV2fxrmNbtDA3N3v_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8","width":300,"height":55}},"lazy":false},{"type":"text","content":"June 10, 2025Announcement no. 16","length":33,"tagName":"p"},{"type":"text","content":"BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy","length":95,"tagName":"p"},{"type":"text","content":"COPENHAGEN, DENMARK and BOSTON, MA, USA, June 10, 2025, (GLOBE NEWSWIRE) - BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR) today announced the appointment of Carsten Buhl as Chief Executive Officer (CEO) of BioPorto A/S and its subsidiaries, effective 1 September 2025, as part of the Company’s succession planning strategy.","length":328,"tagName":"p"},{"type":"text","content":"BioPorto’s current CEO, Peter Mørch Eriksen, will remain in his position until 1 September 2025. Following this date, Peter Mørch Eriksen will support the incoming CEO during the transition period to ensure a smooth and effective onboarding process.","length":249,"tagName":"p"},{"type":"text","content":"Carsten Buhl has spent more than 25 years in the MedTech/life science industries, recently as President of Americas at WSAudiology and part of its executive management. Further, Carsten has experience from senior leadership positions at Natus Medical Inc, Ambu and GN Store Nord.","length":279,"tagName":"p"},{"type":"text","content":"Jens Due Olsen, Chair of BioPorto, stated: "I am pleased to welcome Carsten Buhl to BioPorto. Carsten will be instrumental in launching ProNephro AKI (NGAL)™ in the US market, driving revenue growth and finalizing the clinical studies & submitting an FDA application for adult use in 2026. With a strong background in MedTech/life science, Carsten has a proven track record of driving growth, innovation, and operational excellence. Carsten will be a solid addition to the BioPorto team.”","length":497,"tagName":"p"},{"type":"text","content":"Carsten Buhl, BioPorto’s incoming CEO, com...